2001

• Biovitrum – a new Swedish biotech and biopharma company is established, through spin-out from Pharmacia

2002

• Divests plasma business to Octapharma
• Enters collaboration on therapies for obesity with GlaxoSmithKline.
  

2003

• Signs license agreement with Amgen for innovative treatment of diabetes and other metabolic disorders.
• Creates Biovitrum Biopharmaceuticals, process development and contract manufacturing of protein-based drugs.
  

2004

• Becomes sole supplier of the active protein component in Wyeth's Hemophilia drug ReFacto®
  

2005

• Acquires Cambridge Biotechnology Ltd, a research company in the UK.
• Expands the R&D portfolio by acquiring Arexis, a Swedish biotech and pharmaceutical company.
• Enters collaboration with Santhera for the development of pharmaceuticals for the treatment of diabetes and other metabolic diseases.

2006

• Enters agreement with Syntonix for the joint development of a pharmaceutical for the treatment of Hemophilia.
• Enters agreement with Symphogen for the co-development of a pharmaceutical for the treatment of certain blood disorders.
• Markets six specialist pharmaceuticals primarily in the Nordic countries (ReFacto®, Aloxi®, Novastan®, Mimpara®, Kepivance® and Kineret®).
• Introduced on the Stockholm stock exchange.

2007

• Launches Aloxi®, a new drug in Nordic countries against nausea from chemotherapy
• Martin Nicklasson becomes new CEO
• Starts to co-promote BeneFIX® in the Nordic countries
• Future Roadmap - Increased focus on Protein Therapeutics and Specialist Care diseases
• Exercise its option to partner, with Syntonix/Biogen Idec, on Factor VIIIFc with prolonged half-life for the treatment of hemophilia A

2008

• Initiates the process to find partners for early stage Primary Care projects
• Implements strategic restructuring of the R&D Organization
• Extends ReFacto® Supply Agreement with Wyeth until December 31, 2015
• Biovitrum's and Syntonix's Novel Factor IXFc for Hemophilia B has Received Orphan Drug Designation From the FDA
• Biovitrum and Amgen Announce Close of Product Acquisition Deal to acquire Kepivance® and Stemgen® and an exclusive license for Kineret®
  

2009

• Spins-out Cambridge Biotechnology
• Refacto AF® is launched on the market
• Enters agreement with Karolinska Development
• Gets access to Affibody® Technology
• Investor acquires 23 percent of Biovitrum
• Transfers two Metabolic Disease Projects to iNovacia
• Appoints the Bank of New York Mellon as Depositary Bank
• Selects Megapharm as distributor in Israel
• Together with Biogen Idec Announces Decision to Advance Long-Acting Hemophilia B Therapy into a Registrational Trial
• Kiobrina(TM) shows positive phase II results in preterm infants
• Expands Kineret® License to Include Certain Orphan Indications
• Advances Novel Factor VIII Long-Acting Hemophilia A Therapy into Clinical Trials
• Sells Obesity Program to AstraZeneca

2010

• Completes the acquisition of Swedish Orphan International Holding AB and resolves on an issue in kind
• Biogen Idec and Swedish Orphan Biovitrum Announce First Patient Dosed in Global Registrational Trial of Long-Acting Hemophilia B Therapy
• Biogen Idec and Swedish Orphan Biovitrum Update Hemophilia Partnership Agreement